In these trying times caused by the Coronavirus pandemic, we sincerely hope all of you are doing well. We all look to a brighter future. We have been continuously engaged as a part of the effort to ...
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the ...
PLANO, TX / ACCESSWIRE / October 14, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company") today announced the execution of a binding letter of intent (the "LOI") to merge with BioClonetics ...
BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, ...
We are making great progress on our plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus.
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the ...
We are making great progress on our plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus.
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback